Joel E. Shaffer
Research Triangle Park
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Joel E. Shaffer.
Journal of Pharmacological and Toxicological Methods | 1999
Channa Jayawickreme; Howard Sauls; Natalie Bolio; Jason Ruan; Mary Moyer; Will Burkhart; Brian Edward Marron; Thomas Rimele; Joel E. Shaffer
A cell-based, lawn format assay utilizing an in situ photocleavage method has been developed that allows the rapid examination of large bead-based compound libraries as discrete molecules. The format uses frog melanophore cells in a contiguous, adherent, confluent layer in small petri dishes covered with a 0.5-1-mm layer of agarose containing 130 micron diameter TentaGel beads at a density of 2-20 beads/mm2. Employing this technique a 9-mer, 442,368-member peptide library (designed around the 13 amino acid alpha-MSH peptide sequence) made up of 12 separate pools of 36,864 peptides/pool was assayed. Initially, a fraction (approximately 10%) of each pool was scanned (approximately 3700 beads from each pool) in 60-mm petri dishes to identify the most active pools. Upon direct photocleavage of the beads with UV light (365 nm), each petri dish was photographed over a 60-min period with a CCD camera to record changes in light intensity as an index of melanosome dispersion. Active beads were those that were surrounded by a localized decrease in light transmittance indicating melanosome dispersed cells. Upon examination with a dissecting microscope, single beads centrally located to a circular array of dispersed cells were identified and removed from the agarose and sequenced by Edman degradation to determine the peptide sequence. Re-synthesized peptides were re-examined against alpha-MSH receptor to confirm and quantify the activity. Several 9-mer peptides were identified with potencies similar to the natural 13-mer peptide. This method allows for the rapid screening of large bead-based photo-cleavable peptide libraries with the advantage that each compound is screened as a discrete molecule in a well-less format.
Journal of Medicinal Chemistry | 1997
Judd Berman; Kathy Halm; Kim Adkison; Joel E. Shaffer
Journal of Pharmaceutical Sciences | 1999
Joel E. Shaffer; Kimberly K. Adkison; Kathy Halm; Kevin M. Hedeen; Judd Berman
Archive | 1990
Joel E. Shaffer; Stephen A. Thomson
Archive | 1990
Stephen A. Thompson; Joel E. Shaffer
Archive | 1990
Thomas N. Wheeler; Joel E. Shaffer; Terrence P. Kenakin
Archive | 2001
Jill Elaine Haizlip; Diane M. Ignar; Channa Jayawickreme; Holly Kay King; James A Liacos; Kirsten Marian Mills; Jason Ruan; Howard Sauls; Joel E. Shaffer
Archive | 1991
Thomas N. Wheeler; Terrence P. Kenakin; Joel E. Shaffer
Archive | 2002
Kimberly K. Adkison; Kathy Halm; Joel E. Shaffer; David H. Drewry; Achintya K. Sinhababu; Judd Berman
Archive | 1991
Thomas N. Wheeler; Terrence P. Kenakin; Joel E. Shaffer